Synatra™ personalized resulting system and ClearLLab™ Flow Cytometry platform to deliver precise, patient-specific insights that elevate care for hematologic malignancies.
LAKE FOREST, Calif., July 24, 2025 /PRNewswire-PRWeb/ -- EmeritusDX, a leading innovator in advanced diagnostic solutions, proudly announces the launch of its Hematopathology services, offering state-of-the-art diagnostic, prognostic, and predictive testing for hematologist-oncologists and their patients nationwide. This strategic expansion compliments it's successful solid tumor division.
EmeritusDX's specialized Hematopathology laboratory integrates cutting-edge technologies for the diagnosis and monitoring of neoplastic diseases. At the forefront of this innovation is Synatra™, a personalized case assessment platform that combines all medically necessary technologies to deliver precise, patient-specific insights. Synatra™ empowers physicians to tailor treatment strategies and improve outcomes across the spectrum of hematologic diseases.
A key feature of the new offering is Flow Cytometry performed on the Beckman Coulter DX Flex using ClearLLab™ Antibody Solutions. Beckman Coulter is revolutionizing leukemia and lymphoma analysis in clinical flow cytometry laboratories with the FDA-cleared and CE-marked ClearLLab™ 10C system. This integrated immunophenotyping solution utilizes DURA Innovations dry reagent technology for lymphoid and myeloid lineages.
"We designed our Hematopathology program with precision and efficiency at its core to give providers every tool they need to deliver life-saving care," said Robert Embree, CEO of EmeritusDX. "By leveraging technologies like Beckman Coulter's ClearLLab™ Solutions and our Synatra™ platform, we are redefining how hematologic diseases are diagnosed and monitored."
EmeritusDX's comprehensive Hematopathology menu includes:
- Morphology & Immunohistochemistry (IHC): Expert analysis to support precise tissue characterization.
- Flow Cytometry: 10-color laser analysis with FDA-cleared ClearLLab™ panels for AML, MM, PNH, LGL, and more.
- FISH Testing: Probes for ALL, AML, CLL, CML, MDS, and other blood disorders.
- Molecular Testing: Advanced assays including JAK2, FLT3, NPM1, BCR/ABL qRT-PCR, and T-/B-cell clonality analysis.
- Cytogenetics: Chromosome karyotyping for AML, CLL, MPN, MDS, and NHL.
- Next Generation Sequencing (NGS): Comprehensive panels for detailed genetic insights.
- MyWay™: A unique tool analyzing current results alongside patient medical history to monitor chronic conditions and personalize care plans.
EmeritusDX provides industry-leading turnaround times, STAT Alert™ notifications for acute cases within 24 hours, and Direct Connect™ access for physicians to consult directly with hematopathologists.
About Us:
EmeritusDX is a leading cancer diagnostics and information company specializing in the delivery of actionable clinical insights. From our state-of-the-art laboratory, we provide testing that supports the accurate diagnosis and effective treatment of cancer. We proudly partner with hospital and private pathology laboratories, biotechnology firms, academic institutions, contract research organizations, and pharmaceutical development companies. Our partners rely on the precision and timeliness of our results—and we are unwavering in our commitment to excellence
Media Contact
Charles Caymus, EmeritusDX, 1 949.418.7225, [email protected], www.emeritusdx.com
SOURCE EmeritusDX
Share this article